LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This includes a program of targeted price reductions for several Harrow products and a ...

A program from National Health Service (NHS) England will bring optical coherence tomography (OCT) scans “closer to home” for thousands of patients. As part of an effort to improve outcomes for ...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio.

The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025. The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act ...

A press release from the NIH announced that its scientific team has defined elements of brain-based visual impairment in children. Cerebral or cortical visual impairment (CVI) “has emerged as a ...

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development. Arctic Vision has signed a new commercial collaboration agreement with ...